Clinical trial
Inner-City Anti-IgE Therapy for Asthma
NCT00377572 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00377572 |
|---|---|
| Title | Inner-City Anti-IgE Therapy for Asthma |
| Official title | Inner-City Anti-IgE Therapy for Asthma (ICAC-08) |
| Acronym | ICATA |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Inner-City Asthma Consortium |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Biological |
| Interventions | omalizumab, omalizumab placebo |
| Enrollment | 419 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 18, 2006 |
| Last update posted | Mar 21, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: